114 related articles for article (PubMed ID: 20029337)
1. Immunosuppressive regimen influences incidence of skin cancer in renal and pancreatic transplant recipients.
Loeffelbein DJ; Szilinski K; Hölzle F
Transplantation; 2009 Dec; 88(12):1398-9. PubMed ID: 20029337
[No Abstract] [Full Text] [Related]
2. Neoplastic skin lesions in Iranian renal transplant recipients: the role of immunosuppressive therapy.
Zamanian A; Farshchian M
J Drugs Dermatol; 2007 Jul; 6(7):703-6. PubMed ID: 17763593
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous melanoma is related to immune suppression in kidney transplant recipients.
Vajdic CM; van Leeuwen MT; Webster AC; McCredie MR; Stewart JH; Chapman JR; Amin J; McDonald SP; Grulich AE
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2297-303. PubMed ID: 19622722
[TBL] [Abstract][Full Text] [Related]
4. Kaposi's sarcoma in renal transplant recipients: a report on 26 cases from a single institution.
Qunibi WY; Barri Y; Alfurayh O; Almeshari K; Khan B; Taher S; Sheth K
Transplant Proc; 1993 Feb; 25(1 Pt 2):1402-5. PubMed ID: 8442155
[No Abstract] [Full Text] [Related]
5. Increased risk of squamous-cell carcinoma in simultaneous pancreas kidney transplant recipients compared with kidney transplant recipients.
Wisgerhof HC; van der Boog PJ; de Fijter JW; Wolterbeek R; Haasnoot GW; Claas FH; Willemze R; Bouwes Bavinck JN
J Invest Dermatol; 2009 Dec; 129(12):2886-94. PubMed ID: 19571820
[TBL] [Abstract][Full Text] [Related]
6. Update on the pathogenesis of post-transplant skin cancer in renal transplant recipients.
Ho WL; Murphy GM
Br J Dermatol; 2008 Feb; 158(2):217-24. PubMed ID: 18070205
[TBL] [Abstract][Full Text] [Related]
7. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
[No Abstract] [Full Text] [Related]
8. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study.
Stratta RJ; Alloway RR; Lo A; Hodge E
Transplantation; 2003 Apr; 75(8):1260-6. PubMed ID: 12717213
[TBL] [Abstract][Full Text] [Related]
9. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy.
Geusau A; Dunkler D; Messeritsch E; Sandor N; Heidler G; Rödler S; Ankersmit J; Zuckermann A; Tschachler E
Int J Dermatol; 2008 Sep; 47(9):918-25. PubMed ID: 18937654
[TBL] [Abstract][Full Text] [Related]
10. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
Gruber SA; Gillingham K; Sothern RB; Stephanian E; Matas AJ; Dunn DL
Clin Transplant; 1994 Aug; 8(4):388-95. PubMed ID: 7949545
[TBL] [Abstract][Full Text] [Related]
11. Prevention of acute rejection with antithymocyte globulin (Thymoglobuline): its potential to reduce corticosteroids.
Cantarovich D
J Nephrol; 2004; 17 Suppl 8():S40-6. PubMed ID: 15599885
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive standards in simultaneous kidney-pancreas transplantation.
Schmied BM; Müller SA; Mehrabi A; Welsch T; Büchler MW; Zeier M; Schmidt J
Clin Transplant; 2006; 20 Suppl 17():44-50. PubMed ID: 17100700
[TBL] [Abstract][Full Text] [Related]
13. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
Knight RJ; Villa M; Laskey R; Benavides C; Schoenberg L; Welsh M; Kerman RH; Podder H; Van Buren CT; Katz SM; Kahan BD
Clin Transplant; 2007; 21(4):460-5. PubMed ID: 17645704
[TBL] [Abstract][Full Text] [Related]
15. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
[TBL] [Abstract][Full Text] [Related]
16. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients.
Klauser R; Zlabinger GJ; Traindl O; Franz M; Watschinger B; Pohanka E; Kudlacek S; Kovarik J
Transplant Proc; 1992 Feb; 24(1):292-4. PubMed ID: 1539284
[No Abstract] [Full Text] [Related]
17. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
18. [Incidence of tumors in renal transplant patients. Is there a changing tumor pattern in these patients?].
Hermida Gutiérrez JF; Moreno Sierra J; Blázquez Izquierdo J; Gómez Vegas A; Silmi Moyano A; Prats Sánchez D; Fernández Pérez C; Resel Estévez L
Arch Esp Urol; 1998 Sep; 51(7):683-91. PubMed ID: 9807894
[TBL] [Abstract][Full Text] [Related]
19. [Testicular tumor in renal and pancreatic transplantation].
Karam G; Vasse N; Cathelineau X; Buzelin F; Buzelin JM
Prog Urol; 1998 Jun; 8(3):408-9. PubMed ID: 9689676
[TBL] [Abstract][Full Text] [Related]
20. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants.
Otley CC; Coldiron BM; Stasko T; Goldman GD
Arch Dermatol; 2001 Apr; 137(4):459-63. PubMed ID: 11295926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
